AU2021104048A4 - A novel polyherbal extract having antidiabetic potential - Google Patents
A novel polyherbal extract having antidiabetic potential Download PDFInfo
- Publication number
- AU2021104048A4 AU2021104048A4 AU2021104048A AU2021104048A AU2021104048A4 AU 2021104048 A4 AU2021104048 A4 AU 2021104048A4 AU 2021104048 A AU2021104048 A AU 2021104048A AU 2021104048 A AU2021104048 A AU 2021104048A AU 2021104048 A4 AU2021104048 A4 AU 2021104048A4
- Authority
- AU
- Australia
- Prior art keywords
- day
- group
- diabetes
- plants
- polyherbal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 14
- 230000003178 anti-diabetic effect Effects 0.000 title abstract description 8
- 239000003472 antidiabetic agent Substances 0.000 title abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 36
- 241000700159 Rattus Species 0.000 claims abstract description 32
- 241000196324 Embryophyta Species 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 241000335053 Beta vulgaris Species 0.000 claims abstract description 27
- 235000013500 Melia azadirachta Nutrition 0.000 claims abstract description 26
- 235000021533 Beta vulgaris Nutrition 0.000 claims abstract description 25
- 244000294611 Punica granatum Species 0.000 claims abstract description 25
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 24
- 239000008103 glucose Substances 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000012676 herbal extract Substances 0.000 claims abstract description 4
- 240000005343 Azadirachta indica Species 0.000 claims abstract 9
- 230000000694 effects Effects 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- 241001083505 Punica Species 0.000 claims description 5
- -1 elixirs Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 6
- 230000035876 healing Effects 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 244000119298 Emblica officinalis Species 0.000 claims 1
- 235000015489 Emblica officinalis Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 230000006698 induction Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000003188 neurobehavioral effect Effects 0.000 abstract 1
- 244000237986 Melia azadirachta Species 0.000 description 17
- 230000006399 behavior Effects 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000557821 Azadirachta Species 0.000 description 5
- 240000002234 Allium sativum Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000021537 Beetroot Nutrition 0.000 description 3
- 244000136948 Ocimum sanctum Species 0.000 description 3
- 235000004072 Ocimum sanctum Nutrition 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 244000302512 Momordica charantia Species 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 244000250129 Trigonella foenum graecum Species 0.000 description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- DPBVYZVSXAZMAY-UHFFFAOYSA-N Macaranganin Natural products OC1=C(O)C(O)=CC(C(=O)OC2C(C3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OCC(C3OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 DPBVYZVSXAZMAY-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000011205 Ocimum Nutrition 0.000 description 1
- 241001529734 Ocimum Species 0.000 description 1
- INAAWUYFPBBBCN-UHFFFAOYSA-N Punicafolin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4c(O)c(O)c(O)c(O)c4c5c(O)c(O)c(O)c(O)c5C(=O)OC(C3OC(=O)c6cc(O)c(O)c(O)c6)C2OC(=O)c7cc(O)c(O)c(O)c7 INAAWUYFPBBBCN-UHFFFAOYSA-N 0.000 description 1
- 229920001264 Punicafolin Polymers 0.000 description 1
- 229920000864 Punicalin Polymers 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000016614 betalains Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000001607 nephroprotective effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- IQHIEHIKNWLKFB-ITTSEVFZSA-N pumcalin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1OC(=O)C1=CC(O)=C(O)C(O)=C11)O)O)OC(=O)C2=CC(O)=C(O)C(O)=C2C2=C(O)C(O)=C(OC3=O)C4=C2C(=O)OC2=C4C3=C1C(O)=C2O IQHIEHIKNWLKFB-ITTSEVFZSA-N 0.000 description 1
- DPBVYZVSXAZMAY-UUUCSUBKSA-N punicafolin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]([C@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@H]([C@H]3OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 DPBVYZVSXAZMAY-UUUCSUBKSA-N 0.000 description 1
- SSIRGMIVWUBXFB-UHFFFAOYSA-N punicalin Natural products OC1OC2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)c(O)c5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8cc(C(=O)OC2C(O)C1O)c(O)c(O)c8O SSIRGMIVWUBXFB-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
:
The present invention polyherbal compositition of an extract of a blend of plants, wherein the
plants are ethanolic extract of leaves of Punica granatum, Beta vulgaris, and Azadirachta Indica
in alloxan-induced diabetic rats.
Animals were induced with diabetes using Alloxan and then were observed on basis of numerous
parameters to access the induction and control of diabetes in comparison to all groups. The
animal received dosing of Herbal extracts in treated groups and were checked for Fasting blood
glucose. Neurobehavioral studies & weight of all animals checked on 7,14,21,28 days after
induction of diabetes.
The results proved that the herbal extract of the powder was anti-diabetic in action. Furthermore,
the present also describes a process for the preparation of the polyherbal composition.
Description
Background of Invention:
Diabetes mellitus is a complex, chronic metabolic disease, with heterogeneous etiology and risk factors at the social level and behavioral, environmental, and genetic susceptibility. There are numerous traditional medicinal plants reported having hypoglycemic properties such as Allium sativum (Garlic), Azadirachta indica (Neem), Punica granatum (Anar), Trigonellafoenum (Fenugreek), Momordica charantia (Bitter ground), Ocimum sanctum (Tulsi). The use and delivery of herbal medicine as a dosage form in treating and preventing diseases has a long history started with use in Mesopotamia in 2600 B.C. Although the oldest record on the practice of medicinal plants for drug preparation was engraved on a Sumerian clay slab, created over 5,000 years ago. The use of medicinal plants is still continuing in this modem era, and it has been estimated that approximately one-fourth of prescription medicines worldwide are derived from plants.
FIELD OF INVENTION The present invention relates to herbal compositions for use in diabetes.
Diabetes mellitus is a complex, chronic metabolic disease, with a heterogeneous etiology and risk factors at the social level and behavioral, environmental, and genetic susceptibility. It is a disorder of glucose metabolism and is classified into multiple types based on underlying pathophysiology. The two most common types of diabetes are type 1 and type 2. According to World Health Organization the diabetic population is likely to increase up to 300 million or more by the year 2025. There is increasing demand by patients to use natural products with Antidiabetic activity due to side eff ects associated with the use of insulin and oral hypoglycemic agents.
There are numerous traditional medicinal plants reported to have hypoglycemic properties such as Allium sativum (Garlic), Azadirachta indica (Neem), Punicagranatum (Anar), Trigonellafoenum (Fenugreek), Momordica charantia (Bitter ground), Ocimum santum (Tulsi). Red beetroot (Beta vulgaris L.), is a vegetable that is traditionally consumed throughout the world, and is a source of antioxidant compounds.
The presence of different phenolic compounds in beetroots confers antioxidant properties to this vegetable and recent studies have highlighted the role of nitrate derived from beetroots in reducing blood pressure and reducing type 2 diabetes mellitus . The herbal extracts which are effective in lowering blood glucose level with minimal or no side effects are known to be used as Antidiabetic remedies. Many compounds isolated from these plants are used in combinational therapy for diabetes. Azadirachta indicais known to possess hypolipedimic, hypoglycemic, immunostimulant and hepatoprotectives properties,.. There are reports showing plant extracts exerting beneficial effects in the diabetic environment by improving insulin action. Chemical constituents of the leaf extract of Punica granatumareellagic acid, tannins (punicalin and punicafolin), and flavone glycosides, including luteolin and apigenin.
DETAILED DESCRIPTION OF THE INVENTION Before the present methods and systems are disclosed and described, it is to be understood that the methods and systems are not limited to specific synthetic methods, specific components, or to particular compositions. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. The present invention describes
a polyherbal composition of following herbs. Punica Granatum:
Fermented juice of pomegranate fruit has been found to have antioxidant activity. Extracted juice of pomegranate flowers can reduce blood sugar and lipids. Azadirachta Indica: According to the report oral feeding of ethanolic extract of Azadirachta indica leaves increased beta cell density and decreased oxidative stress in the pancreas of STZ-induced diabetic rats also showed regenerative action of this extract in alloxan-induced diabetic rats .It is also traditionally used as tonic and astringent for wounds, tooth decay and gum diseases. Beta vulgaris leaf
B. vulgaris leaves contain various phytoconstituents such as betalains, flavonoids, polyphenols, vitamins, and minerals. They have antioxidant, anticancer, hepatoprotectives, nephroprotective, wound healing, and anti- inflammatory activities. Phytochemical screening of chard has revealed the presence of some fatty acids, phospholipids, glycolipids, polysaccharides, folic acid, ascorbic acid, and pectin. In addition, saponins andflavonoids reported to have hypoglycemic effects, have also been found in various Beta vulgaris species
In a preferred embodiment, the present invention relates to a synergistic polyherbal composition comprising of an extract of a blend of plants, wherein the plants are selected from a group consisting of powder of dried fruits of Punica Granatum, Beta vulgaris leaf &Azadirachta Indica.
In one embodiment, the polyherbal composition is present in the form of powder, granules, liquid, solid, or semisolid. The present invention also provides a polyherbal composition useful for lowering blood sugar level and hyperlipidemia. In a preferred embodiment, the polyherbal composition can be used as an adjuvant or complementary treatment to an existing or conventional anti-diabetic therapy. In one embodiment, the process of preparation of polyherbal composition comprises of: (i) washing raw plant parts followed by drying to obtain dried plant parts; (ii) obtaining a fine powder by powdering and optionally sieving the dried plant parts to obtain fine powders of each of the plant parts; (iii) mixing the fine powders of each of the plant parts of step (ii) in a specific ratio to form a polyherbal powder (PHP) of plant parts; and (iv) extracting the polyherbal powder of step (iii) using a solvent to obtain an extract and concentrating said extract to obtain the polyherbal composition. In a preferred embodiment, the blend of plants comprises of powder of dried fruits of Punica Granatum
Beta vulgaris leaf &Azadirachta Indica.
Animal Studies:
Healthy albino male rats of Wistar strain approximately of same age group weighing 100-150 g weight of rats somewhat lower than standard, but the rats were otherwise healthy, 6-8 weeks old, took normal average daily diet, and displayed normal daily activity and behavior. The experiment is carried out during 9am to 4:30 after noon on daily basis up to 28 days. Male rats were obtained from the Animal House,. The animals were housed in standard cages and maintained under controlled room temperature (25± °C) and humidity (55 5%) with 12:12 hour light and dark cycle. The rats were fed commercially available rat normal pellet diet and water ad libitum.
The above drugs were administered orally once daily for 28 days. A total of 10 animals were equally divided into five groups with two animals in each group as shown in table 1.
TABLE 1: Experimental design for animal activity is shown in below given table.
S. No Group Drug Dose
1. A(normal normal saline 10ml/kg/d control)
2. B (diabetes normalSaline 10ml/kg/d control)
3. C zandu diabrishta -21 ayurvedic arishta preparation 0.5ml/kg/d
Pvt.Lmt (standard) manufactured by Emami
4. D Ethanolic extract of polyherbal powder of leaves of Punica 100mg/kg/d Indica (treated 1) granatum, Beta vulgaris and Azadirachta
5. E Ethanolic extract of polyherbal powder of leaves of Punica 200
mg/kg/d (treated 2) granatum, Beta vulgaris and Azadirachta Indica
Induction of Diabetes:
Leaving aside two rats for normal control group, diabetes was induced in eight rats by a single intraperitoneal injection of alloxan monohydrate in the dose of 150 mg/kg body weight. The fasting blood glucose was determined after 72 hours. Eight rats showing a blood glucose level of >200 mg/100 ml were taken for the study. Blood samples were collected using Retro orbital method.
Collection of blood sample and blood glucose estimation:
Blood samples were drawn from eyes of rat that using Retro orbital method, at weekly intervals till the end of the study (i.e. 4 weeks). Fasting blood serum glucose estimation was done on 7th, 14th, 21st and
28th day. Blood glucose estimation was done by glucose diagnostic Kits manufactured by call on plus Pvt. Ltd., using glucose strip. The complete process if explained in flowchart in figure 1.
Acute Toxicity Studies:
Albino rats of male sex were used for acute oral toxicity test according to the Organization for Economic Cooperation and Development (OECD) guidelines 10 Wistar rats weighing 100-200gm were selected and divided into five groups containing two animals per group. The animals were fasted overnight and were provided with only water. All groups were administered 10mg/kg body weight ethanolic extract of poly herbal powder of Punica granatum, Beta vulgaris and Azadirachta Indicaorally and observed for 14
days. If mortality was observed in one animal, then the same dose was repeated again to confirm toxic dose. If mortality was not observed, the procedure was repeated for further higher doses such as 1000, 2000&3000 mg/kg body weight.The treated animals were carefully observed individually for the toxicity signs and mortality. Parameters such as changes in skin and fur, eyes, respiratory, behavioral pattern, tremors, convulsions salivation, diarrhoea, lethargy, sleep and coma were observed.
Effect on body weight and Fasting Blood Sugar Level in Diabetic Rats:
On repeated administration of the extract for 28 days , a significant decrease in blood sugar was found in Groups C, D and E as compared to Group B , which showed a significant rise in blood sugar as compared to that in Group C,D and E . The percentage of reduction in body weight and fasting blood glucose in groups C, D and E on the 7h 14h 21s, and 2 8 th day is shown in figure 2,3
Behavior Activity: General Behavior Studies:
Evaluation of general behavioral profiles was performed by the method. Albino Wistar rats were divided in to fivegroup's two animals in each group. Ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indicawas administered to group D and E at dose of 100 and
200mg/kg body weight respectively. While the group A and B receives normal saline 10ml/kg .Group C wasadministered with Antidiabetic syrup named as zandu diabrishta -21 ayurvedic arishta preparation manufactured by Emami Pvt. Ltd. (0.5 mg/kg/day orally) The animals were under observation for theirbehavioral changes if any, at 30 min intervals in the first one hour and at the hourly intervals for the next 4 hour for the following parameters. Awareness, Alertness and Spontaneous Activity: The awareness and alertness was recorded by visual measure of the animal's response when placed in a different position and its ability to orient itself without bumps or falls. Animals usually show a moderate degree of inquisitive behavior.Sound Response: Albino Wistar rats normally utter no obnoxious sounds, so vocalization may indicate a noxious stimulus.
Elevated maze plus
The elevated plus maze has been described as a simple method for assessing anxiety responses of rodents by File and co-workers. There is great diversity in possible applications of the elevated plus maze. To name a few, prescreening of newly developed pharmacological agents for treatment of anxiety-related disorders can be carried out. The anxiolytic and anxiogenic effects of pharmacological agents, drugs of abuse and hormones can be investigated. The effects of reproductive senescence aging and pre or postnatal exposure to various stressors can be assessed . Behavioral responses in the elevated plus maze are easily assessed and quantified by an observer. Briefly, rodents are placed in the intersection of the four arms of the elevated plus maze and their behavior is typically recorded for 5 min. This was based upon the early studies that revealed that rats demonstrated the most robust avoidance responses in the first 5 min after placement in the elevated open alleys. The behaviors that are typically recorded when rodents are in the elevated plus maze are the time spent and entries made on the open and closed arms. Behavior in this task (i.e., activity in the open arms) reflects a conflict between the rodent's preference for protected areas (e.g., closed arms) and their innate motivation to explore novel environments. Anti anxiety behavior (increased open arm time and/or open arm entries) can be determined simultaneously with a measure of spontaneous motor activity (total and/or closed arm entries). Rats were divided in to five groups consisting of 2 rats per group. Ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica was administered to group D and E at dose of 100 and
200mg/kg body weight respectively. While the group A and B receives normal saline 10ml/kg .Group C was administered with Antidiabetic syrup named as zandu diabrishta -21 ayurvedic arishta preparation manufactured by Emami Pvt.Lmt. (0.5 mg/kg/day orally. On the first training day, each animal was placed at the end of an open arm facing away from the central platform.) Readings were taken as the time taken by the rat to move into any one of the covered arms with all its four legs. If the animal did not enter into the one of the arm within 90secs, it was gently pushed into one of the covered arms and the reading was assigned as 90secs. The animals was allowed to explore to the maze for 10secs and then returned to its home cage. This was examined on 6, 13,20and 27 day of drug treatment. Significant reduction in transfer latency value indicates improvement in memory. (figure 5)
Figure 5: Effect of ethanolic extract polyherbal powder of leaves of Punicagranatum, Beta vulgaris and AzadirachtaIndica on Elevated maze plus
Desxcription of the Invention
Diabetes is a common chronic ailment for which the patient has to take insulin to maintain the blood sugar level. It is very interesting to see how Polyherbal extract tackles this problem. It corrects the function of pancreas, stimulating it to produce insulin in the natural way, which in turn maintains the
blood sugar level. Polyherbal extract revitalizes and rejuvenates the organs, the dysfunction of which is causing the disease. This brings back normal functioning of the organs. Since no artificial chemicals are involved, it doesn't cause any side effects .Upon administration of ethanolic extract of polyherbal powder of leaves of Punicagranatum, Beta vulgaris and Azadirachta Indica significant changes were recorded in
blood glucose levels. Blood glucose levels in normal and diabetic rats along with other rats after oral administration of ethanolic extract of polyherbal powder of leaves of Punicagranatum, Beta vulgaris and Azadirachta Indica are summarized in Tables 3and 4, respectively. The administration of 100mg/kg/d ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta
Indica caused a decrease of blood glucose in treated 1 rat that is group D but less than standard drug. The administration of 200 mg/kg/d ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica decreased blood glucose levels indiabetic rats more than that of standard drug and 100mg/kg/d ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica respectively. The administration of standard decrease the blood glucose level equal to group D.
Upon administration of ethanolic extract of polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica significant changes were recorded in blood glucose levels. Blood glucose levels in normal and diabetic rats along with other rats after oral administration of ethanolic extract was compared. The results obtained from the present study show that the polyherbal powder of punica granatum, Beta vulgaris and Azadirachta indica had beneficial effects on lowering blood glucose levels. This polyherbal powder appears to be an attractive material for further studies, leading to possible drug development for diabetes. Development of phytomedicine is relatively inexpensive and less time consuming; it is more suited to our economic conditions than allopathic drug development which is more expensive and spread over several years. Popularity of natural products or their derivatives role in diseases cure and prevention is increasing worldwide due to less side effect properties.
Claims (7)
1. A polyherbal compositition comprising of an extract of a blend of plants, wherein the plants are selected from a group consisting of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica.
2. The polyherbal compositition as claimed in claim 1, wherein amount of Punica Grantum ranges 25 to30% by weight, amount of Beta vulgaris ranges from 15 to 30% by weight, amount of Azadirachta Indica ranges from 25 to 35% by weight.
3. The polyherbal composition as claimed in claim 1, wherein the blend of plants comprises of powder of leaves of Punica Grantum, powder of leaves of Beta vulgaris, and powder of leaves of Azadirachta Indica.
4. The polyherbal composition as claimed in claim 1, wherein the composition comprises of pharmaceutically or veterinary or nutritionally acceptable excipients.
5. The polyherbal composition as claimed in claim 1, wherein the polyherbal composition is in a dosage form, wherein the dosage form is selected from a group consiting of tablets, soft capsules, hard capsules, pills, granules, powders, emulsions, suspensions, sprays, syrups, elixirs, and pellets.
6. The polyherbal composition as claimed in claim 1, wherein the polyherbal composition is used in treatment of diabetes.
7. A process for preparation of the polyherbal composition as claimed in claim 1, the process comprising: (i) washing and drying plants to obtain dried plants; (ii) powdering and optionally sieving the dried plants obtained in step (i) to obtain fine powders of each of the dried plants; (iii) blending the fine powders of each of the dried plants obtained in step (ii) to obtain a blend of plants; and (iv) extracting the blend of plants of step (iii) using a solvent to obtain an extract of a blend of plants and concentrating the extract of the blend of plants and optionally adding excipients to obtain the polyherbal composition; wherein the plants are selected from the group consisting of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica.
Art Work
Plants involved in formation of herbal extract 2021104048
Dry leaves of Punica granatum, Beta vulgaris and Azadirachta indica
Figure 1: Flow chart of animal activity showing diabetes.
Dry Leaves of Azadirachta indica Dry Leaves of punica granatum Dry Leaves of beta vulgaris
Ethanolic extract of polyherbal formulation of beta vulgaris, Azadirachta indica and punica granatum (500ml ethanol: 180 gm. powder)
Diabetes induced in rats (group B, C, D and E by a single intraperitoneal injection of alloxan monohydrate in the dose of 150 mg/kg body weight.
After diabetes induced to animals dosing will be done in animals. 2021104048
Group–A: Group–B: Diabetic Group–C: Group–D: Group-E: Normal Control Control (Normal market Treated 1st Treated 2nd (Normal Saline; Saline; 10 ml/kg/d) formulation of (100 mg/kg) (200 mg/kg) 10 ml/kg/d) amla will be given (0.5
Group-D Group- A provided Group- B Group-E provided provided with with normal pellets provided with with normal Group-C normal pellets diet and water. normal pellets pellets diet water provided with diet water and Fasting of rats done diet and water. and (200mg/kg/d) th , th normal pellets (100 mg/kg/d) on 0, 6 , 13th 20 Fasting of rats ethanolic extract. th diet water and ethanolic extract. and 27 day and done on 0, 6 , th Fasting of rats (0.5mg/kg/d)aml Fasting of rats Glucose level checked , th 13th 20 and 27 th th done on 0, 6th, st th th st a syrup. Fasting done on 0, 6 , on 1 , 7 , 14 , 21 day and Glucose , th th 13th, 20th and th of rats done on 13th 20 and 27 and 28 day. level checked on th th th 27th day and 0, 6 , 13 ,20 day and Glucose Diabetes is not th th 1st, 7 , 14 , 21 st th Glucose level and 27 day and level checked on induced th and 28 day. th th st checked on 1st, Glucose level 1st, 7 , 14 , 21 Diabetes is checked on 1st, th and 28 day 7th, 14th, 21st th th st induced 7 , 14 , 21 and and 28th day th 28 day
Group A will show Group C will Group D will show Group E will show normal activity. Group B will show healing healing affect from healing affect from become weak due affect from diabetes. diabetes more to diabetes. diabetes. accurate then group B and C.
M 300 g/ dl 250 2021104048
200 Day 0 150 Day 7 Day 14 100 Day 21 Day 28 50
0 Normal control Diabetes control Standard zandu Treated 1 Treated 2 10ml/kg/d 10ml/kg/d dabrishta 100mg/kg/d 200mg/kg/d 0.5ml/kg/d
Figure 3: Effect of ethanolic extract polyherbal powder of leaves of Punica granatum, Beta vulgaris and Azadirachta Indica on fasting blood serum glucose level of alloxan induced diabetic albino rats.
300
M 250 2021104048
g/ dl 200 * day 0 150 day 7 day 14 100 day 21 day 28 50
0 Normal control Diabetes control Standard zandu Treated 1 Treated 2 10ml/kg/d 10ml/kg/d dabrishta 100mg/kg/d 200mg/kg/d 0.5ml/kg/d
30
25
20
15 Day 0
10 Day 28
5
0 Normal Diabetes Standard Treated 1 Treated 2 control control dabrishta 100mg/kg/d 200mg/kg/d 10ml/kg/d 10ml/kg/d 0.5ml/kg/d
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021104048A AU2021104048A4 (en) | 2021-07-11 | 2021-07-11 | A novel polyherbal extract having antidiabetic potential |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021104048A AU2021104048A4 (en) | 2021-07-11 | 2021-07-11 | A novel polyherbal extract having antidiabetic potential |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021104048A4 true AU2021104048A4 (en) | 2021-09-09 |
Family
ID=77563754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021104048A Ceased AU2021104048A4 (en) | 2021-07-11 | 2021-07-11 | A novel polyherbal extract having antidiabetic potential |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021104048A4 (en) |
-
2021
- 2021-07-11 AU AU2021104048A patent/AU2021104048A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rahman et al. | Anti-inflammatory, antinociceptive and antidiarrhoeal activities of methanol and ethyl acetate extract of Hemigraphis alternata leaves in mice | |
Ayyanar et al. | Traditional herbal medicines used for the treatment of diabetes among two major tribal groups in South Tamil Nadu, India | |
DE602004012745T2 (en) | SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS | |
Mishra et al. | Asparagus racemosus: Chemical constituents and pharmacological activities—A review | |
IOR et al. | Anti-inflammatory and analgesic activities of the ethanolic extract of the leaf of Syzygium guineense in rats and mice | |
EP1829548A1 (en) | Use of Pelargonium sidoides extracts in combination with Plantago lanceolata extracts for the preparation of a medicament for the treatment of pharyngitis | |
Mbaka et al. | Anti-hyperglycaemic and hypoglycaemic effects of ethanol root extract of Sphenocentrum jollyanum in normal and alloxan-induced diabetic rabbits | |
Kaur et al. | Diabetes and antidiabetic herbal formulations: an alternative to Allopathy | |
Varma et al. | Hypoglycemic activity of Putranjiva roxburghii wall. In alloxan induced diabetic rats | |
Njike et al. | Hypoglycaemic activity of the leaves extracts of Bersama engleriana in rats. | |
Tenpe et al. | Comparative evaluation of antidiabetic activity of some marketed polyherbal formulations in alloxan induced diabetic rats | |
Choubey et al. | Hypoglycemic and antihyperglycemic effect of ethanolic extract of whole plant of Lawsonia inermis (henna) in streptozotocin induced diabetic rats | |
AU2021104048A4 (en) | A novel polyherbal extract having antidiabetic potential | |
Borquaye et al. | Anti-inflammatory, antioxidant and total phenolic content of the ethanolic extracts of Celtis africana Burm. f | |
Sinha et al. | Anti diabetic potential of herbal plants and polyherbal formulation | |
Sheikhpour et al. | A survey on herbal medicines for hypoglycemia in diabetic patients | |
Bhat | Action of arecanut (Areca Catechu L.) and its chewing forms on laboratory animals and its implication on human carcinogenesis-An assessment | |
Pal et al. | Anti-diabetic action of polyherbal ethanolic extract in alloxan-induced diabetes in Wistar rats | |
Shaikh et al. | Antihyperglycemic and Antihyperlipidemic Activity of Sida spinosa linn. Root in Streptozotocin-Induced Diabetic Rats | |
Taherian et al. | Anti-Inflammatory Effect of Launaea Acanthodes Gum | |
Momoh et al. | Toxicological and hypoglycemic studies on the oil extracted from seeds of Khaya senegalensisis on blood glucose levels of alloxan-induced diabetic albino rats | |
Mushtaq et al. | Role of Momordica charantia L. As herbal medicine to cure hyperglycemia in vitro on induced diabetic model animals | |
Ghanekar et al. | Antidiarrheal evaluation of aqueous extract of Garcinia indica & Cuminum cyminum and a polyherbal formulation | |
Liyanaarachchie et al. | In vitro antidiabetic and in vivo hypoglycaemic activities and toxicity of Canarium zeylanicum bark extracts | |
DE60216979T2 (en) | Synergistic hepatoprotective composition of trans-tetracos-15-enoic acid and apocynin and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |